Regulus Therapeutics Inc./$RGLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Ticker
$RGLS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
34
ISIN
US75915K3095
Website
RGLS Metrics
BasicAdvanced
$621M
-
-$0.72
0.37
-
Price and volume
Market cap
$621M
Beta
0.37
52-week high
$8.35
52-week low
$1.22
Average daily volume
1.1M
Financial strength
Current ratio
16.305
Quick ratio
14.866
Long term debt to equity
2.03
Total debt to equity
2.03
Interest coverage (TTM)
-550.55%
Profitability
EBITDA (TTM)
-51.401
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-34.23%
Return on equity (TTM)
-53.82%
Valuation
Price to book
7.88
Price to tangible book (TTM)
7.89
Price to free cash flow (TTM)
-12.356
Free cash flow yield (TTM)
-8.09%
Free cash flow per share (TTM)
-66.44%
Growth
Earnings per share change (TTM)
-49.42%
3-year earnings per share growth (CAGR)
-35.99%
10-year earnings per share growth (CAGR)
-41.45%
Bulls say / Bears say
Novartis's acquisition of Regulus Therapeutics for up to $1.7 billion, including an upfront payment of $7 per share, represents a significant premium over the stock's previous closing price, indicating strong confidence in Regulus's pipeline and potential (reuters.com).
Regulus Therapeutics successfully completed its Phase 1b Multiple-Ascending Dose clinical trial of farabursen (RGLS8429) for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), demonstrating promising results that could lead to further development and commercialization (stocktitan.net).
The appointment of Dr. Rekha Garg as Chief Medical Officer, with extensive experience in kidney disease, strengthens the company's leadership team and enhances its capability to advance its clinical programs (stocktitan.net).
Regulus Therapeutics reported a net loss of $11.0 million for the second quarter of 2024, reflecting ongoing financial challenges and the need for additional capital to sustain operations (stocktitan.net).
The company's total liabilities increased to $7.77 million as of December 2024, indicating a rising debt burden that could impact financial stability (gurufocus.com).
Despite the acquisition announcement, the deal's completion is expected in the second half of 2025, leaving a period of uncertainty that could affect stock performance in the interim (reuters.com).
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RGLS News
AllArticlesVideos
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
Business Wire·2 months ago
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·2 months ago
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regulus Therapeutics Inc. stock?
Regulus Therapeutics Inc. (RGLS) has a market cap of $621M as of June 21, 2025.
What is the P/E ratio for Regulus Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Regulus Therapeutics Inc. (RGLS) stock is 0 as of June 21, 2025.
Does Regulus Therapeutics Inc. stock pay dividends?
No, Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Regulus Therapeutics Inc. dividend payment date?
Regulus Therapeutics Inc. (RGLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. (RGLS) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.